PARK JI HYEON, PARK KYUNG SUN, JANG HYE RYOUN, LEE JUNG EUN, HUH WOOSEONG, KIM YOON-GOO, OH HA YOUNG, KIM DAE JOONG Division of Nephrology, Department of Internal Medicine, Samsung Medical center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea Introduction: Living-unrelated donors (LURD) have been widely click here used for kidney transplantation (KT). We compared clinical outcomes of

KT from LURD and from concurrent living-related donors (LRD), and identified risk factors associated with acute rejection, graft and patient survival in living KT. Methods: We retrospectively reviewed 779 patients who underwent living donor KT (264 from LURD, 515 from LRD) at Samsung Medical Center from January 2000 to December 2012. Results: Median follow-up was 67 months. Mean age (43.2 vs. Protease Inhibitor Library supplier 38.4 years, P < 0.001), mean number of total HLA mismatches (4.1 vs. 2.5, P < 0.001) and HLA-DR mismatches (1.2 vs. 0.8, P < 0.001) were higher, and mean estimated glomerular filtration rate (eGFR) was lower (87.6 vs. 90.9 ml/min, P = 0.007) in LURD. Acute rejection-free survival (64.9% vs. 72.7% at 5 years, P = 0.018) and graft survival (92.9% vs. 96.5% at 5 years, P = 0.025) were lower for LURD than LRD whereas patient survival rate was comparable (97.9% vs. 98.7% at 5 years, P = 0.957). Cox-regression analysis showed that HLA-DR mismatches (OR 1.77, 95% CI 1.20–2.62, P = 0.004

for 1 mismatches; OR 2.63, 95% CI 1.64–4.20, P. Conclusion: Our data suggest that HLA-DR mismatches and donor eGFR are independent risk

factors for clinical outcomes of living KT. In living KT, these factors should be considered to prevent acute rejection and improve graft survival. ADACHI HIROKI, MUKAI KIYOTAKA, OKUSHI YUKI, OKINO KAZUAKI, SHOJIMA KIYO, MATSUI YUKI, FUJIMOTO KEIJI, ATSUMI HIROKATSU, OKUYAMA HIROSHI, YAMAYA HIDEKI, YOKOYAMA HITOSHI Division of Nephrology, Kanazawa Medical University Amisulpride School of Medicine Introduction: Although the risk for morbidity and mortality is studied in subjects with renal transplantation, there are very limited data to access the reno-protective effects of lipid and adiponectin. Methods: We studied 105 adult subjects (age 19- to 72-year old; 66 males, 21 cadaveric donors) between January 2004 and December 2012, with at least three years of allograft survival in our hospital. We examined clinical backgrounds, donor types (living or cadaver), treated drugs, blood pressure (BP, mmHg), body mass index (BMI), blood chemistry including cholesterol (total, LDL-C, HDL-C), glucose, glycated hemoglobin (HbA1c), and total, high- and low-molecular adiponectin (ADPN) levels. Results: The initial 4 years alteration of eGFR was at −2.2(−14.3∼7.0) ml/min/1.73 m2/year in 105 subjects. In single analyses, both LDL-C/HDL-C ratio below 2.0 and statin treatment also decreased the reduction rate of eGFR at −1.4 and −1.0 ml/min/1.73 m2/year (p = 0.01, p = 0.02), respectively, but not by total ADPN levels.